A Phase 1, Open-label, Crossover Study To Evaluate The Bioequivalence Of Intramuscular And Subcutaneous Peginterferon Beta-1a In Healthy Volunteers

被引：0
|
作者：
Zhao, Y. [1 ]
Chen, K. [1 ]
Ramia, N. [1 ]
Sahu, S. [1 ]
Kumar, A. [1 ]
Naylor, M. L. [1 ]
Zhu, L. [1 ]
Butts, C. [1 ]
机构：
[1] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P047
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [1] Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
    Zhao, Yuan
    Chen, Kun
    Ramia, Nancy
    Sahu, Sangeeta
    Kumar, Achint
    Naylor, Maria L.
    Zhu, Li
    Naik, Himanshu
    Butts, Cherie L.
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [2] A PHASE 1 OPEN-LABEL CROSSOVER STUDY TO EVALUATE BIOEQUIVALENCE OF ORAL SUSPENSION AND TABLET FORMULATIONS OF PERAMPANEL IN HEALTHY SUBJECTS
    Laurenza, A.
    Hall, N.
    Majid, O.
    Rege, B.
    [J]. EPILEPSIA, 2016, 57 : 170 - 171
  • [3] Subcutaneous administration of alefacept is bioequivalent to intramuscular administration: Results of a randomized, open-label, crossover study in healthy volunteers
    Sweetser, M
    Ticho, B
    Swan, S
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB224 - AB224
  • [4] COMPARE: a phase 1 pharmacokinetic study of subcutaneous peginterferon beta-1a vs subcutaneous interferon beta-1a over 2 weeks in healthy subjects
    Hu, X.
    Shang, S.
    Nestorov, I.
    Dawson, K.
    Sperling, B.
    Werneburg, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 597 - 598
  • [5] Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
    Alam, J
    McAllister, A
    Scaramucci, J
    Jones, W
    Rogge, M
    [J]. CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 35 - 43
  • [6] Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers
    Mignini, Fiorenzo
    Streccioni, Valentino
    Tomassoni, Daniele
    Traini, Enea
    Amenta, Francesco
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 2007, 29 (08) : 575 - 586
  • [7] Comparative study on the bioequivalence of two formulations of pravastatin - Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers
    Almeida, S
    Filipe, A
    Almeida, A
    Gich, I
    Antonijoan, R
    Puntes, M
    Barbanoj, M
    Caturla, MC
    [J]. ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2006, 56 (02): : 70 - 75
  • [8] Piroxicam Immediate Release Formulations: A Fasting Randomized Open-Label Crossover Bioequivalence Study in Healthy Volunteers
    Helmy, Sally A.
    EL-Bedaiwy, Heba M.
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 466 - 471
  • [9] Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers
    Leong, Chuei Wuei
    Sagim, Elton
    Yee, Kar Ming
    Saharuddin, Muhammad Shalhadi
    Abdullah, Nik Mohd Zulhakimi Nik
    Saberi, Noramirah Farhanah
    Boopathy, Rajavikraman
    Ahmad, Shahnun
    Amran, Atiqah
    Batheja, Raman
    Sharma, Rajan
    Vuppalavanchu, Kiran Kumar
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2023, 12 (01):
  • [10] Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers
    Ino, Hiroko
    Shiramoto, Masanari
    Eto, Takashi
    Haranaka, Miwa
    Irie, Shin
    Terao, Takumi
    Ogura, Hirofumi
    Wakamatsu, Akira
    Hoyano, Keiko
    Nakano, Atsushi
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 805 - 812
12345